Immune Regulation by CD55 in Chronic Beryllium Disease

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• CD55 is an immune regulator inhibiting T cell activation and interacting with CD97.
• CD55 expression is decreased in chronic beryllium disease (CBD), but its role is unclear.
• Downregulation of CD55 in peripheral blood mononuclear cells (PBMCs) may enhance beryllium-specific immune responses in CBD.

Purpose of the Study:

• To investigate the functional role of CD55 downregulation in CBD pathogenesis.
• To characterize CD55 expression and function in PBMCs from individuals with CBD and beryllium sensitization (BeS).
• To elucidate the signaling pathways involved in CD55's effect on beryllium-induced immune responses.

Main Methods:

• Quantified CD55, sCD55, and CD97 mRNA expression using qRT-PCR in PBMCs from CBD, BeS, and control subjects.
• Assessed CD55, STAT1, JAK2, and TNF-α expression following beryllium sulfate (BeSO4) stimulation in CBD PBMCs.
• Measured serum sCD55 via ELISA and conducted functional studies using anti-CD55 antibodies and JAK2 inhibitor TG101348.

Main Results:

• CD55, sCD55, and CD97 mRNA were significantly downregulated in CBD PBMCs compared to BeS.
• Serum sCD55 levels were also reduced in individuals with CBD.
• CD55 blockade enhanced TNF-α production and lymphocyte proliferation in CBD and BeS PBMCs, effects reversed by JAK2 inhibition.

Conclusions:

• CD55 downregulation in CBD amplifies beryllium-induced immune responses.
• The JAK2/STAT1 signaling pathway mediates the effects of CD55 on immune cell activation.
• Targeting CD55 or related signaling pathways may offer therapeutic strategies for CBD.